Blinding in pharmaceutical clinical trials: An overview of points to consider

Contemporary Clinical Trials

Volumn 43, Issue , 2015, Pages 155-163

  Crisp, Adam ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bias; Blinding; Double blind; Randomized controlled trial

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DOUBLE BLIND PROCEDURE; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; NOMENCLATURE; OPEN STUDY; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; QUALITY CONTROL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; SELECTION BIAS; SINGLE BLIND PROCEDURE; STAFF; STATISTICAL ANALYSIS; TRIPLE BLIND PROCEDURE; METHODOLOGY; PATIENT SAFETY; PROCEDURES; STANDARDS;

NEW DRUG;

DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; HUMANS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84930947340     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.06.002     Document Type: Article

References (23)

1. ICH E9 Statistical principles for clinical trials Available at:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.
2. Miller L.E., Stewart M.E. The blind leading the blind: use and misuse of blinding in randomized controlled trials. Contemp. Clin. Trials 2011, 32:240-243.
3. Schulz K.F., Chalmers I., Altman D.G. The landscape and lexicon of blinding in randomized trials. Ann. Intern. Med. 2002, 136:254-259.
4. Schultz K.F., Grimes D.A. Blinding in randomised trials: hiding who got what. Lancet 2002, 359:696-700.
5. Bhatt D.L., Kandzari D.E., O'Neill W.W., D'Agostino R., Flack J.M., Katzen B.T., Leon M.B., Liu M., Mauri L., Negoita M., Cohen S.A., Oparil S., Rocha-Sing K., Townsend R.R., Bakris G.L. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014, 10:1393-1401.
6. Tafinlar US label Available at:, (Accessed 28th May, 2015). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf.
7. ICH E6 Guideline for good clinical practice Available at:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
8. Senn S. Statistical Issues in Drug Development 2008, Wiley. 2nd edn.
9. CONSORT statement http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Statement/CONSORT%202010%20Explanation%20and%20Elaboration%20(BMJ).pdf.
10. Pogue J., Walter S.D., Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin. Trials 2009, 6:239-251.
11. Amit O., Mannino F., Stone A.M., Bushnell W., Denne J., Helterbrand J., Burger H.U. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur. J. Cancer 2011, 47:1772-1778.
12. Ellenberg S.S., Fleming T.R., DeMets D.L. Data Monitoring Committees in Clinical Trials: A Practical Perspective 2002, Wiley.
13. Mehta C.R., Pocock S.J. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat. Med. 2010, 10.1002/sim.4012.
14. FDA Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pd.
15. ICH E2A Clinical safety data management: definitions and standards for expedited reporting http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
16. ICH E3 Structure and content of clinical study reports http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf.
17. Bang H., Flaherty S., Kolahi J., Park J. Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol. Clin. Res. Regul. Aff. 2010, 27(2):42-51.
18. Jamshidian F., Hubbard A.E., Jewell N.P. Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomized clinical trials. Stat. Methods Med. Res. 2014, 23(3):293-307.
19. Bang H., Ni L., Davis C.E. Assessment of blinding in clinical trials. Control. Clin. Trials 2004, 25:143-156.
20. Freed B., Assall O.P., Panagiotakis G., Bang H., Park J.J., Moroz A., Baethge C. Assessing blinding in trials of psychiatric disorders: a meta-analysis based on blinding index. Psychiatry Res. 2014, 219:241-247.
21. Schulz K.F., Altman D.G., Moher D., Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet 2010, 375:1144-1146.
22. Kolahi J., Bang H., Park J.J., Desbiens N.A. CONSORT 2010 and controversies regarding assessment of blindness in RCTs. Dent. Hypotheses 2010, 2:99-105.
23. Hopton A.K., MacPherson H. Assessing blinding in randomized controlled trials of acupuncture: challenges and recommendations. Chin. J. Integr. Med. 2011, 17(3):173-176.